Astria Therapeutics, Inc.
ATXS
$5.86
-$0.03-0.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -69.15% | 18.41% | -38.40% | -92.36% | -78.12% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.69% | 4.03% | 10.79% | 31.29% | 67.81% |
| Change in Net Operating Assets | -141.19% | 660.57% | -439.36% | 1,171.53% | 58.60% |
| Cash from Operations | -78.16% | 42.58% | -96.14% | -56.98% | -44.07% |
| Capital Expenditure | -- | 100.00% | -400.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 122.64% | -85.85% | -- | -17.05% | -164.73% |
| Cash from Investing | 122.64% | -84.38% | 154,800.00% | -17.58% | -164.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | 13,810.00% | -65.57% | 383,162.16% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.00% | 13,810.00% | -65.57% | 383,162.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -54.49% | -137.83% | 54.24% | -24.08% | -101.94% |